Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efmarodocokin alfa - Genentech

Next Previous
Drug Profile

Efmarodocokin alfa - Genentech

Alternative Names: IL-22Fc; RG-7880; RO 7021610; UTTR1147A

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; Roche
  • Class Anti-inflammatories; Foot disorder therapies; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Interleukin-22 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued COVID-19 pneumonia; Crohn's disease; Diabetic foot ulcer; Graft-versus-host disease; Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 29 Sep 2023 Genentech terminates a phase-II trial in Ulcerative colitis and Crohn's disease in the US, Bulgaria, Georgia, Germany, Greece, Ireland, Italy, Moldova, Poland, Russia, Serbia, Spain, Ukraine, United Kingdom (unspecified route) (NCT03650413)
  • 24 Feb 2023 Genentech completes a phase I trial in Graft-versus-host disease (Combination therapy, Prevention) in USA (IV) (NCT04539470)
  • 13 Feb 2023 Discontinued - Phase-I for Diabetic foot ulcer (Treatment-experienced) in Denmark, Hungary, USA, Italy, United Kingdom, Spain (SC) (Roche pipeline, February 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top